To help you make sense of it all and get even more insight, we tapped Steve Silvestro, MD, DABOM, FAAP
Preclinical studies in diet-induced-obese mice had shown no toxicity or adverse reaction at doses five times higher than those required to effect weight loss
GIP/GLP-1/glucagon (GCG) triple agonists represent a particularly exciting new drug class that is being studied in patients with obesity
Notably, researchers observed no similar reduction in hospitalizations unrelated to alcohol in T2D populations and smaller impacts on hospitalizations unrelated to alcohol in populations with obesity, suggesting the effect may be specific to alcohol-related outcomes, rather than confounding by underlying health status or general improvements in health
The New England Journal of Medicine, 387 (3), 205216
Reduced disruption to daily activities Consider the practical reality